Hemab
Hemab is a clinical-stage biotech company developing prophylactic therapeutics, like sutacimig, for serious bleeding and thrombotic disorders.
Secondary Market Price
How Hemab Measures Up
To help you manage your Hemab equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Hemab's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Hemab Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Hemab's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Hemab Therapeutics is a clinical-stage biotechnology company that develops prophylactic therapeutics for bleeding and thrombotic disorders. The company is advancing a pipeline of monoclonal and bispecific antibody-based treatments for conditions with high unmet need, including Glanzmann Thrombasthenia, Von Willebrand Disease, and Factor VII deficiency. Founded in 2020, Hemab established operations in both Cambridge, Massachusetts, and Copenhagen, Denmark. Early in its history, the company secured exclusive licenses to antibody technologies from Novo Nordisk and Genmab to support its research and development.
Looking forward, the company is operating under a strategic plan called Hemab 1-2-5, which outlines a goal to develop five clinical assets by 2025. Recent progress includes the advancement of clinical trials for Von Willebrand Disease and the presentation of positive results from a Phase 2 study of its drug candidate, sutacimig, for Glanzmann thrombasthenia. In November 2025, Hemab secured US$157 million in a Series C funding round to support its continued development efforts.
- Sofinnova Partners
- RA Capital Management
- Novo Holdings
- Access Biotechnology
- Deep Track Capital
- HealthCap
- Invus
- Avoro Ventures
- Maj Invest Equity
- Rock Springs Capital
- Avoro Capital Advisors
- Co-Founder, Johan Henrik Faber
- Co-Founder, Søren Bjørn
- Co-Founder, Hans Wandall
- Co-Founder, Thomas Batchelor
- Co-Founder, Mads Behrndt
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Hemab worth joining?
Deciding whether to join a private company like Hemab requires a careful evaluation of its equity compensation package and future growth potential. Tools like Prospect can help you compare potential equity outcomes and make an informed career decision.
What should I do with my Hemab stock?
The right strategy for your Hemab stock depends on your personal financial goals, risk tolerance, and tax situation. Platforms like Prospect offer customized strategies for exercising options and selling shares to help you maximize your returns.
Can you sell Hemab stock?
Selling stock in a private company like Hemab is typically possible during specific liquidity events, such as tender offers or secondary sales, but it is not as simple as selling public stock. Prospect provides tools and guidance to help you navigate these opportunities and determine the tax-optimal time to sell.
How can I find the value of my Hemab stock?
Valuing stock in a private company like Hemab can be challenging as it isn't publicly traded, but it's often based on the latest 409A valuation or recent funding rounds. Prospect uses predictive models trained on venture capital data to help you forecast the future value of your shares.
What is Hemab's equity worth?
The precise worth of Hemab's equity is not public information and depends on the company's private valuation, which can change with new funding rounds or performance. You can use platforms like Prospect to get data-driven projections on what your specific equity holdings could be worth in various scenarios.
What is Hemab's stock ticker symbol?
As a private company, Hemab does not have a stock ticker symbol because its shares are not traded on a public stock exchange. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO).
Can I buy or sell Hemab stock?
Selling Hemab stock is typically possible during company-approved liquidity events, while buying shares is generally restricted to employees or accredited investors in private funding rounds. While Prospect does not facilitate the buying of shares, it provides tools to help you optimize the sale of your existing equity.
What is the criteria to buy or invest in Hemab stock?
Investing in a private company like Hemab is typically limited to employees as part of their compensation or to accredited investors who participate in private financing rounds. These opportunities are not generally available to the public until the company pursues an IPO.
